Forward this message to a colleague.
Wednesday, May 27, 2015  |  Volume 7 / Number 11  |  A Production of the BioProcessing Journal
Career Development
CMC Strategy Forum
Summer 2015
July 20–21, 2015
Gaithersburg, Maryland USA
Suggested Reading
Design and Optimization of a Purification Process for MY32/Ls Protein Solubilizing Inclusion Bodies for a New Vaccine Against Sea Lice
By Carlos Perez Heredia, Center for Genetic Engineering and Biotechnology (CIGB)
Havana, Cuba, et al.
Sponsored Link
LIMIT RISK of BATCH FAILURE with TRAINING at WPI
When the process is the product, employee competence is your biggest risk.
Make the Biomanufacturing Education and Training Center at WPI an extension of your training program so your team can hone their skills and learn new capabilities in our pilot plant where the processes are real, but product is not at risk.

Working together, we can deliver customized hands-on programs just for your team. Or you can send staff to our open enrollment programs. The goal is to limit the risk of batch failure with skills development, cross-training, error prevention, and troubleshooting.


508–831-4879

Products & Services
Cell Culture Growth Supplement Formulated to Replace Bovine Serum
ZenBio, Inc. has released a new GroPro™ Cell Culture Growth Supplement. The GroPro product line allows for culturing of primary cells and cell lines without the concern for transmission of bovine prions and xenogeneic reactions.

This new GroPro supplement is a convenient, ready-to-use human platelet lysate (HPL) formulation that can be used at the same supplementation percentages as fetal bovine serum (FBS) in traditional cultures, but does not require the addition of heparin. HPL has proven to be an excellent, cost effective substitute for FBS in cell culture growth medium without the risk of xenogeneic infections or immune reactions.

For more information, please visit zen-bio.com.
First Successful Clone of an Anti-Ebola Therapeutic Antibody Product Candidate
XBiotech, the developer of True Human™ therapeutic antibodies, has successfully isolated and cloned an anti-Ebola product candidate using its True Human antibody discovery platform. The anti-Ebola product candidate was developed from a blood donation received earlier this year from a patient who recovered from Ebola infection.

XBiotech's broad pipeline of True Human antibodies are able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, True Human antibodies retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body.

For more information, please visit xbiotech.com.
Techno-Blast Masthead
Mammalian fibroblast cells.

Email your cell images to the editor today!
Advertising
Economize by combining Techno-Blast and BioProcessing Journal advertising into one package.

Don't finalize your media plans for 2015 without consulting our media kit!
Email us to request a copy.
Career Development
BPJ Publishing






Update your profile and email address.
Or did a colleague forward this to you? Subscribe here.
While we'd hate to see you go, you can unsubscribe instantly.

[[tracking_beacon]]